Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
See detailLa récolte des résidus de coupe face au développement durable de la forêt
Carnol, Monique ULg

Conference given outside the academic context (2003)

Actuellement, la discussion sur les enjeux environnementaux de l’utilisation des ‘déchets’ ligneux pour la production d’énergie porte exclusivement sur la contribution de cette pratique dans les efforts ... [more ▼]

Actuellement, la discussion sur les enjeux environnementaux de l’utilisation des ‘déchets’ ligneux pour la production d’énergie porte exclusivement sur la contribution de cette pratique dans les efforts de réduction des émissions de gaz à effet de serre et sur l’augmentation de la contribution des énergies renouvelables à la production totale d’énergie. Dans ces ‘déchets’ on trouve les sciures, les chutes de bois et d’autres résidus de l’industrie du bois, mais également les résidus d’exploitations forestières, généralement laissés sur site. Ces ‘déchets ligneux abandonnés en forêt’ jouent cependant un rôle important dans le recyclage des éléments nutritifs et donc dans la fertilité à long terme du site. Dans une approche budgétaire, quantifiant les entrées (pluies, pluviolessivats, altération des roches) et les sorties (lessivage, exploitation forestière) en nutriments de l’écosystème forêt, on peut estimer l’importance relative de l’exploitation forestière par rapport aux réserves nutritives du sol. Pour les sols pauvres de l’Ardenne, il apparaît que les éléments nutritifs des résidus de coupe peuvent jouer un rôle important dans le maintien du capital en nutriments du site. Dans le cadre des préoccupations du développement durable de la forêt, il apparaît donc indispensable de mener une réflexion globale sur l’utilisation bois-énergie et d’effectuer les récoltes des résidus sur des sites adéquats afin de ne pas aboutir aux excès de la surexploitation. [less ▲]

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailLa recombinaison chez les alphaherpèsvirus
Meurens, François; Schynts, Frédéric; Thiry, Etienne ULg

in Annales de Médecine Vétérinaire (2001), 145

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailLa recombinaison, moteur de diversité chez les alphaherpèsvirus, a de profondes implications médicales
Thiry, Etienne ULg; Meurens, François; Schynts, Frédéric et al

in Bulletin de l'Académie Royale de Médecine de Belgique (2007), 168

Detailed reference viewed: 17 (0 ULg)
Full Text
Peer Reviewed
See detailA recombinant 31.5 kDa keratinase and a crude exo-antigen from Microsporum canis fail to protect against a homologous experimental infection in guinea pigs.
Descamps, Frederic F; Brouta, Frederic; Vermout, Sandy M et al

in Veterinary Dermatology (2003), 14(6), 305-312

A Microsporum canis recombinant 31.5 kDa keratinase and a M. canis crude exo-antigen were tested as vaccines in an experimental infection model in guinea pigs. Animals were vaccinated subcutaneously three ... [more ▼]

A Microsporum canis recombinant 31.5 kDa keratinase and a M. canis crude exo-antigen were tested as vaccines in an experimental infection model in guinea pigs. Animals were vaccinated subcutaneously three times at two-week intervals with either the keratinase, the exo-antigen or the adjuvant alone. Cutaneous challenge was performed blindly. Both humoral and cellular-specific immune responses to M. canis antigens were evaluated every 14 days, while a blind evaluation of clinical lesion development and fungal persistency in skin were monitored weekly. Vaccination induced very high and significant (P < 0.01) antibody responses towards both antigens. High cell-mediated immune responses to both immunogens were also induced by vaccination. After challenge, however, scores reflecting the severity of dermatophytic lesions did not differ significantly between vaccinated and control groups at any time after challenge. These results suggest that, in the guinea pig, the induction of specific immune responses against the M. canis-secreted antigens used in this study are not protective against challenge exposure. [less ▲]

Detailed reference viewed: 27 (5 ULg)
See detailRecombinant antibody an its application in plant pathogen diagnosis
Tassus, X.; Duterme, O.; Roussel, S. et al

Poster (2004)

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailA recombinant beta-O-glucosidase from Caldocellum saccharolyticum to hydrolyse desulfo-glucosinolates
Wathelet, Jean-Paul ULg; Iori, R.; Leoni, O. et al

in Biotechnology Letters (2001), 23(6), 443-446

Glucosinolates, natural compounds found in Brassicaceae, can easily be transformed into desulfo-glucosinolates by action of Helix pomatia sulfatase. The recombinant beta -O-glucosidase from Caldocellum ... [more ▼]

Glucosinolates, natural compounds found in Brassicaceae, can easily be transformed into desulfo-glucosinolates by action of Helix pomatia sulfatase. The recombinant beta -O-glucosidase from Caldocellum saccharolyticum does not catalyse glucosinolate degradation but can hydrolyse desulfo-glucosinolates (thio-D-glucosidic substrates) to produce the corresponding pure nitriles, including valuable homochiral representatives. [less ▲]

Detailed reference viewed: 26 (1 ULg)
Full Text
Peer Reviewed
See detailRecombinant bovine herpesvirus 4 (BoHV-4) expressing glycoprotein D of BoHV-1 is immunogenic and elicits serum-neutralizing antibodies against BoHV-1 in a rabbit model.
Donofrio, Gaetano; Cavirani, Sandro; Vanderplasschen, Alain ULg et al

in Clinical and Vaccine Immunology (2006), 13(11), 1246-54

Several biological characteristics of bovine herpesvirus 4 (BoHV-4) make it a good candidate as a gene delivery vector for vaccination purposes. These characteristics include little or no pathogenicity ... [more ▼]

Several biological characteristics of bovine herpesvirus 4 (BoHV-4) make it a good candidate as a gene delivery vector for vaccination purposes. These characteristics include little or no pathogenicity, unlikely oncogenicity, the capability to accommodate large amounts of foreign genetic material, the ability to infect several cell types coming from different animal species, and the ability to maintain transgene expression in both undifferentiated and differentiated cells. Starting from BoHV-4 cloned as a bacterial artificial chromosome (BAC), we used MuA transposase-mediated in vitro transposition to generate recombinant BoHV-4 expressing the immunodominant glycoprotein D (gD) of BoHV-1, one of the most important pathogens of cattle. Although a cis-acting element from woodchuck hepatitis virus (the woodchuck hepatitis virus posttranscriptional regulatory element [WPRE]) in the 3' end of the gD expression cassette was required for maximal gD expression from plasmids in transient transfection assays, this element was not necessary for efficient expression of gD from recombinant BoHV-4 genomes. BoHV-4 recombinants containing gD expression cassettes with or without the WPRE expressed gD at similarly high levels. Several cell lines originating from different animal species expressed gD when infected with BoHV-4 recombinants. When rabbits were immunized with one of the recombinants, high levels of serum neutralizing antibodies against BoHV-1 were generated. This work is one of the first demonstrations of the use BoHV-4 as a vector for vaccine purposes and may provide the basis for BoHV-1 vaccination of cattle with recombinant BoHV-4. [less ▲]

Detailed reference viewed: 29 (12 ULg)
Full Text
Peer Reviewed
See detailRecombinant expression and antigenic properties of a 31.5-kDa keratinolytic subtilisin-like serine protease from Microsporum canis
Descamps, Frédéric; Brouta, Frédéric; Vermout, Sandy et al

in FEMS Immunology & Medical Microbiology (2003), 38(1), 29-34

A secreted 31.5-kDa keratinolytic subtilase (SUB3; AJ431180) is thought to be a Microsporum canis virulence factor and represents a candidate for vaccination trials. In this study, the recombinant ... [more ▼]

A secreted 31.5-kDa keratinolytic subtilase (SUB3; AJ431180) is thought to be a Microsporum canis virulence factor and represents a candidate for vaccination trials. In this study, the recombinant keratinase (r-SUB3) was produced by the Pichia pastoris expression system and purified to homogeneity. Recombinant SUB3 displayed identical biochemical properties with the native protease. Experimentally cutaneously infected guinea pigs showed specific lymphoproliferative response towards r-SUB3, while no specific humoral immune response was induced except for one animal. The heterologous expression of SUB3 provides a valuable tool for addressing further investigations on the role of this keratinase in the specific cellular immune response and on its use in vaccination trials in the cat. (C) 2003 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved. [less ▲]

Detailed reference viewed: 18 (1 ULg)
See detailRecombinant fish hormone proteins.
Rentier-Delrue, Françoise ULg; Martial, Joseph ULg; Renard, André

Patent (1990)

The present invention relates to a recombinant stable polypeptide comprising in its polypeptide chain an aminoacid sequence contained in one of the following amino sequences : * from amino acid (-20) to ... [more ▼]

The present invention relates to a recombinant stable polypeptide comprising in its polypeptide chain an aminoacid sequence contained in one of the following amino sequences : * from amino acid (-20) to amino acid (187) represented in Fig. 2, * from amino acid (1) to amino acid (187) represented in Fig. 2, * from amino acid (1) to amino acid (187) represented in Fig. 2, preceded by Met. [less ▲]

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailRecombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults
Sokal, E. M.; Hoppenbrouwers, K.; Vandermeulen, C. et al

in Journal of Infectious Diseases (2007), 196(12), 1749-1753

Background. To date, there is no commercially available vaccine to prevent infectious mononucleosis, a disease frequently induced by Epstein-Barr virus (EBV) infection in adolescents or adults devoid of ... [more ▼]

Background. To date, there is no commercially available vaccine to prevent infectious mononucleosis, a disease frequently induced by Epstein-Barr virus (EBV) infection in adolescents or adults devoid of preexisting immunity to the virus. Methods. A total of 181 EBV-seronegative, healthy, young adult volunteers were randomized in a double-blind fashion to receive either placebo or a recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and 3-O-desacyl-4'-monophosphoryl lipid A (AS04) candidate vaccine in a 3-dose regimen. Results. The vaccine had demonstrable efficacy (mean efficacy rate, 78.0% [95% confidence interval {CI}, 1.0% -96.0%]) in preventing the development of infectious mononucleosis induced by EBV infection, but it had no efficacy in preventing asymptomatic EBV infection. One month after receipt of the final dose of gp350 vaccine, 98.7% of subjects showed seroconversion to anti-gp350 antibodies (95% CI, 85.5%-97.9%), and they remained anti-gp350 antibody positive for > 18 months. Furthermore, there were no concerns regarding the safety or reactogenicity of the gp350/AS04 vaccine. Conclusion. These data support the clinical feasibility of using an EBV vaccine to prevent infectious mononucleosis. [less ▲]

Detailed reference viewed: 76 (0 ULg)
Full Text
Peer Reviewed
See detailRecombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
Vanstraelen, Gaëtan; Baron, Frédéric ULg; Willems, Evelyne ULg et al

in Experimental hematology (2006), 34(7), 841-50

PURPOSE: After allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning (NMHCT), many patients experience prolonged anemia and require red blood cell (RBC) transfusions. We ... [more ▼]

PURPOSE: After allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning (NMHCT), many patients experience prolonged anemia and require red blood cell (RBC) transfusions. We enrolled 60 consecutive patients undergoing NMHCT in a phase II trial to determine the optimal utilization of recombinant human erythropoietin (rHuEPO) therapy in this setting. PATIENTS AND METHODS: The first 14 NMHCT recipients did not receive rHuEPO (control group). Nineteen patients were scheduled to start rHuEPO on day 0 (EPO group 2) and 27 patients on day 28 after the transplant (EPO group 1). RHuEPO was administered subcutaneously once weekly at a dose of 500 U/kg/wk with the aim of achieving hemoglobin (Hb) levels of 13 g/dL. The 3 groups were well balanced for major characteristics. RESULTS: During the first month (p < 0.0001) as well as days 30 to 100 (p < 0.0001) and days 100 to 180 (p < 0.0001), Hb values were higher in patients receiving rHuEPO compared to those not receiving it. However, transfusion requirements were significantly decreased only in the first month in EPO group 2 (p = 0.0169). T-cell chimerism above 60% on day 42 was the best predictor of Hb response (p < 0.0001) or Hb correction (p = 0.0217), but myeloid chimerism above 90% also predicted for Hb response (p = 0.0069). Hb response was also decreased in patients receiving CD8-depleted grafts and increased in the few patients not receiving TBI, but only in univariate analysis. CONCLUSIONS: Anemia after NMHCT is sensitive to rHuEPO therapy, but less so than after conventional allogeneic HCT. RHuEPO decreases transfusion requirements only in the first 30 days posttransplant. T-cell chimerism below 60% on day 42 impaired Hb response, suggesting possible inhibition of donor erythropoiesis by residual recipient lymphocytes. A prospective randomized trial should be performed with rHuEPO starting on the day of transplantation to assess its clinical benefit in terms of transfusion requirements and quality of life. [less ▲]

Detailed reference viewed: 49 (4 ULg)
Full Text
Peer Reviewed
See detailRecombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
Baron, Frédéric ULg; Frere, Pascale ULg; Fillet, Georges ULg et al

in Clinical Cancer Research : An Official Journal of the American Association for Cancer Research (2003), 9(15), 5566-72

PURPOSE: Previous trials of recombinant human erythropoietin (rHuEpo) therapy after autologous hematopoietic stem cell transplantation have administered very high doses of i.v. rHuEpo starting on day 1 ... [more ▼]

PURPOSE: Previous trials of recombinant human erythropoietin (rHuEpo) therapy after autologous hematopoietic stem cell transplantation have administered very high doses of i.v. rHuEpo starting on day 1 and continuing for 1-2 months until erythroid engraftment and have shown no benefit of rHuEpo therapy. We sought to establish a more effective use of rHuEpo in this setting. EXPERIMENTAL DESIGN: In this report, we show in a first cohort of 45 lymphoma or myeloma patients undergoing peripheral blood stem cell transplant (control group) that endogenous erythropoietin levels are high for the degree of anemia during the first 3 weeks after transplant but become adequate or slightly decreased thereafter. We thus enrolled 41 consecutive similar patients in a trial of rHuEpo therapy at a dose of 500 units/kg/week started on day 30 after the transplant. RESULTS: The 12-week probability of achieving hemoglobin (Hb) levels of 13 g/dl was 87% in rHuEpo-treated patients versus 14% in controls (P = 0.0001). Mean Hb levels were significantly higher in the rHuEpo group than in the control group from day 42 through day 150 after transplant (Ps of <0.05 to <0.001). Two of 41 patients in the rHuEpo group versus 12 of 45 patients in the control group had Hb levels of <9 g/dl between day 42 and day 100 after the transplant (P = 0.0078). CONCLUSIONS: Anemia after autologous peripheral blood stem cell transplant is exquisitely sensitive to rHuEpo when therapy is started soon after engraftment. This is the first convincing report showing that rHuEpo is effective in this setting. Our data set the stage for a more rational use of rHuEpo after autologous hematopoietic stem cell transplantation and should renew interest in erythropoietin therapy in this setting. Prospective, randomized trials should investigate the impact of rHuEpo therapy on transfusion requirements and quality of life. [less ▲]

Detailed reference viewed: 21 (0 ULg)
Full Text
Peer Reviewed
See detailRecombinant human estrogen, androgen and progesterone receptors for detection of potential endocrine disruptors
Scippo, Marie-Louise ULg; Argiris, Catherine; Van de Weerdt, Cécile ULg et al

in Analytical and Bioanalytical Chemistry (2004), 378(3), 664-669

This work reports the binding capacity of various chemicals (so-called endocrine disruptors) to recombinant human steroid receptors (hERalpha, hPR and hAR). The tested chemicals are organochlorine ... [more ▼]

This work reports the binding capacity of various chemicals (so-called endocrine disruptors) to recombinant human steroid receptors (hERalpha, hPR and hAR). The tested chemicals are organochlorine insecticides (DDT and its metabolites, methoxychlor, aldrin, dieldrin, chlordecone, lindane, trichlorobenzene), estrogenic insecticides (endosulfan, toxaphene, nonachlor), herbicides (alachlor and atrazine), fungicides (benomyl and vinclozolin), industrial chemicals (nonylphenol, bisphenol A, diphenylphtalate), antioxidants (butylated hydroxyanisol) and some phytoestrogens. Except for phytoestrogens, most of the tested chemicals (DDT and its metabolites, aldrin, alpha- and beta-endosulfan, toxaphen, trans-nonachlor) show higher affinities for hPR than for hERalpha, indicating that the interaction with the progesterone receptor could contribute to the endocrine-disrupting effects imputed to these chemicals. We propose to use binding assays using recombinant human steroid receptors as screening tools for the detection of endocrine disruptors in various samples. [less ▲]

Detailed reference viewed: 58 (12 ULg)
Full Text
Peer Reviewed
See detailRecombinant Interferon alfa-2c versus polychemotherapy (VMCP) for treatment of multiple myeloma : a prospective randomized trial
Ludwig, H.; Cortelezzi, A.; Scheithauer, W. et al

in European Journal of Cancer & Clinical Oncology (1986), 22

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailA recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3) and a vaccine for the prevention of a desease caused by KHV/CyHV-3 in Cyprinus carpio or Cyprinus carpio koi
Costes, Bérénice ULg; Lieffrig, F.; Vanderplasschen, Alain ULg

in EP 07115093.2 (2007)

The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and to a ... [more ▼]

The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and to a vaccine for preventive and/or therapeutic treatment of a disease caused by koi herpesvirus (KHV) or CyHV-3. The 5 recombinant herpesvirus is used to confer immunity on fish, preferably on carps, more preferably on Cyprinus carpio, against a disease caused by koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3). [less ▲]

Detailed reference viewed: 65 (3 ULg)
Peer Reviewed
See detailRecombinant Production Of The P10(Cks1at) Protein From Arabidopsis Thaliana And C-13 And N-15 Double-Isotopic Enrichment For Nmr Studies
Landrieu, I.; Casteels, P.; Odaert, B. et al

in Protein Expression & Purification (1999), 16(1),

Detailed reference viewed: 11 (3 ULg)
Peer Reviewed
See detailRecombinant prolactin Receptor Extracellular Domain of Rainbouw trout (Oncorhynchus mykiss): subcloning, preparation and characterization
Sandowski, Y.; Cohen, Y.; Le Rouzic, P. et al

in General and Comparative Endocrinology (2000), 118

The cDNA of the extracellular domain of rainbow trout (Oncorhynchus mykiss) prolactin receptor (trPRLR-ECD) was cloned in the prokaryotic expression vector pMON to enable its expression in Escherichia ... [more ▼]

The cDNA of the extracellular domain of rainbow trout (Oncorhynchus mykiss) prolactin receptor (trPRLR-ECD) was cloned in the prokaryotic expression vector pMON to enable its expression in Escherichia coli after induction with nalidixic acid. The bacterially expressed trPRLR-ECD protein, contained within the refractile body pellet, was solubilized in 4.5 M urea, refolded, and purified on a Q-Sepharose column, pH 8, by stepwise elution with NaCl. The bioactive monomeric 26-kDa fraction was eluted in 0.2 M NaCl, yielding 20 mg/2.5 L of induced culture. The purified protein was over 98% homogeneous, as shown by SDS-PAGE in the presence or absence of reducing agent and by chromatography on a Superdex column. Binding experiments using [125I]ovine placental lactogen (oPL) as a ligand revealed that human growth hormone (hGH), oPL, and ovine prolactin (oPRL) were the most effective competitors, with respective IC50 values of 1.32, 2.27, and 2.70 nM. Chicken (ch) PRL did not compete at all, and homologous trPRL was much less effective, with a corresponding IC50 value of 1826 nM. Gel-filtration was used to determine the stoichiometry of trPRLR-ECD's interaction with oPL, hGH, and oPRL. Only oPL yielded a 2:1 complex, whereas hGH and oPRL formed only 1:1 complexes, with excess trPRLR-ECD being seen at the initial 2:1 trPRLR-ECD:hGH or trPRLR-ECD:oPRL ratios. No studies were performed with chPRL because of its inability to compete with [125I]oPL or with trPRL because of its low affinity toward trPRLR-ECD. The present results agree with previous findings indicating, as in mammals, that homologous PRL interacts transiently with its receptor and suggest that transient homologous PRL-induced homodimerization of the receptor is sufficient to initiate a biological signal, despite the fact that, in classical binding experiments, only low specific binding can be detected. [less ▲]

Detailed reference viewed: 7 (0 ULg)